Function of L-Type Ca2+ Channels in B-Lymphocytes

B 淋巴细胞中 L 型 Ca2 通道的功能

基本信息

  • 批准号:
    7575751
  • 负责人:
  • 金额:
    $ 19.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-03-01 至 2011-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Calcium (Ca2+) plays a central role in Biology as a universal messenger by allowing cells to efficiently respond to extracellular signals via modulation of its intracellular level. The permeability of cellular membranes for Ca2+ ions is therefore carefully regulated by membrane proteins called ion channels. The mounting of an efficient immune response also requires an extended period of intracellular Ca2+ elevation in immune cells such as lymphocytes. B-lymphocytes are the cells of the adaptive immune system that are responsible for the production of antibodies. The diversity of ion channels expressed in B lymphocytes is greater than originally anticipated, and includes molecules such as L-type CaV-channel variants that were originally assumed to be specific for so-called excitable cells, such as cardiac or neuronal cells. Although the presence of these L-type channels in B-cells is well established, their function remains to be elucidated. The aim of this proposal is to establish genetic model systems allowing us to investigate the role of individual members of the L-type channel family in the B-cell context. This includes the generation and functional characterization of B-cell lines lacking L-type channels that can subsequently be complemented with wildtype and mutant versions of the channels. We also plan to analyze the function of these molecules in vivo by studying the effect of B-cell restricted genomic deletion of L-type channels in an existing mouse model. Because the immune response is a very complex interplay of numerous cell types in multiple locations of the body, this in vivo model represents a complementary approach to the cell lines that will allow us to study the potential role of L-type channels in B-cell development and activation in the context of the complete organism. Public Health Relevance Statement: L-type Ca2+ channels are important therapeutic targets of a class of drugs that include verapamil and diltiazem, which are commonly used to treat conditions such as hypertension in patients. It has been shown in vitro that these drugs also inhibit the Ca2+-response of immune cells, although at higher concentrations than these applied therapeutically. This suggests that immune specific variants of these channels exist that are less sensitive towards these compounds. A promising avenue of immuno-modulatory drug development is therefore to design modified versions of these known channel inhibitors that would specifically bind and inhibit the immune system versions of L-type channels. To this aim, it is essential to identify the functional variants of these channels expressed in the immune context, and their precise role during immune response activation. Furthermore, these findings could also be beneficial to young patients suffering from rare complex genetic disorders affecting L-type channel function, and who are known to show symptoms consistent with immuno-deficiencies. This proposal will contribute to answering these important questions by investigating the role of these channels in B-lymphocytes.
描述(由申请人提供):钙(Ca 2+)在生物学中作为通用信使发挥核心作用,通过调节其细胞内水平使细胞有效响应细胞外信号。因此,细胞膜对Ca 2+离子的渗透性受到称为离子通道的膜蛋白的仔细调节。有效免疫应答的建立还需要免疫细胞(如淋巴细胞)中细胞内Ca 2+升高的延长时间。B淋巴细胞是适应性免疫系统的细胞,负责产生抗体。在B淋巴细胞中表达的离子通道的多样性大于最初预期的,并且包括诸如L型CaV通道变体的分子,其最初被假定为对所谓的可兴奋细胞(诸如心脏或神经元细胞)具有特异性。虽然这些L型通道在B细胞中的存在是公认的,但它们的功能仍有待阐明。该提案的目的是建立遗传模型系统,使我们能够调查的L型通道家族的个别成员在B细胞的情况下的作用。这包括缺乏L型通道的B细胞系的产生和功能表征,其随后可以用野生型和突变型通道补充。我们还计划通过研究现有小鼠模型中B细胞限制性基因组缺失L型通道的影响来分析这些分子的体内功能。由于免疫反应是身体多个部位的多种细胞类型的非常复杂的相互作用,因此这种体内模型代表了细胞系的补充方法,这将使我们能够研究L型通道在B细胞发育和激活中的潜在作用。公共卫生相关性声明:L-型Ca 2+通道是一类药物的重要治疗靶点,包括维拉帕米和地尔硫卓,它们通常用于治疗患者的高血压等疾病。体外研究表明,这些药物也抑制免疫细胞的Ca 2+反应,尽管浓度高于治疗应用的浓度。这表明存在这些通道的免疫特异性变体,其对这些化合物不太敏感。因此,免疫调节药物开发的一个有希望的途径是设计这些已知通道抑制剂的修饰形式,其将特异性结合并抑制L型通道的免疫系统形式。为此,必须确定这些通道在免疫环境中表达的功能变体,以及它们在免疫应答激活过程中的确切作用。此外,这些发现也可能对患有影响L型通道功能的罕见复杂遗传疾病的年轻患者有益,并且已知这些患者表现出与免疫缺陷一致的症状。这项建议将有助于回答这些重要的问题,通过调查这些通道在B淋巴细胞中的作用。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Signature Channels of Excitability no More: L-Type Channels in Immune Cells.
兴奋性的签名通道不再:免疫细胞中的L型通道。
  • DOI:
    10.3389/fimmu.2015.00375
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Davenport B;Li Y;Heizer JW;Schmitz C;Perraud AL
  • 通讯作者:
    Perraud AL
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANNE-LAURE PERRAUD其他文献

ANNE-LAURE PERRAUD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANNE-LAURE PERRAUD', 18)}}的其他基金

The TRPM2 Ion Channel in Hepatic Innate Immunity
肝脏先天免疫中的 TRPM2 离子通道
  • 批准号:
    8882242
  • 财政年份:
    2014
  • 资助金额:
    $ 19.5万
  • 项目类别:
The TRPM2 Ion Channel in Hepatic Innate Immunity
肝脏先天免疫中的 TRPM2 离子通道
  • 批准号:
    8702878
  • 财政年份:
    2014
  • 资助金额:
    $ 19.5万
  • 项目类别:
Novel Transgenic Mouse Models to Analyze TRPM2 and ADP-Ribose Function
用于分析 TRPM2 和 ADP-核糖功能的新型转基因小鼠模型
  • 批准号:
    8603848
  • 财政年份:
    2013
  • 资助金额:
    $ 19.5万
  • 项目类别:
Novel Transgenic Mouse Models to Analyze TRPM2 and ADP-Ribose Function
用于分析 TRPM2 和 ADP-核糖功能的新型转基因小鼠模型
  • 批准号:
    8493695
  • 财政年份:
    2013
  • 资助金额:
    $ 19.5万
  • 项目类别:
Function of L-Type Ca2+ Channels in B-Lymphocytes
B 淋巴细胞中 L 型 Ca2 通道的功能
  • 批准号:
    7450983
  • 财政年份:
    2008
  • 资助金额:
    $ 19.5万
  • 项目类别:
Cellular regulation of magnesium homeostasis
镁稳态的细胞调节
  • 批准号:
    6884661
  • 财政年份:
    2004
  • 资助金额:
    $ 19.5万
  • 项目类别:
Cellular regulation of magnesium homeostasis
镁稳态的细胞调节
  • 批准号:
    7413402
  • 财政年份:
    2004
  • 资助金额:
    $ 19.5万
  • 项目类别:
Cellular regulation of magnesium homeostasis
镁稳态的细胞调节
  • 批准号:
    7228548
  • 财政年份:
    2004
  • 资助金额:
    $ 19.5万
  • 项目类别:
Cellular regulation of magnesium homeostasis
镁稳态的细胞调节
  • 批准号:
    6774303
  • 财政年份:
    2004
  • 资助金额:
    $ 19.5万
  • 项目类别:
Cellular regulation of magnesium homeostasis
镁稳态的细胞调节
  • 批准号:
    7057799
  • 财政年份:
    2004
  • 资助金额:
    $ 19.5万
  • 项目类别:

相似海外基金

Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9981001
  • 财政年份:
    2017
  • 资助金额:
    $ 19.5万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9751102
  • 财政年份:
    2017
  • 资助金额:
    $ 19.5万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9397073
  • 财政年份:
    2017
  • 资助金额:
    $ 19.5万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    10223410
  • 财政年份:
    2017
  • 资助金额:
    $ 19.5万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
  • 批准号:
    7951676
  • 财政年份:
    2008
  • 资助金额:
    $ 19.5万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
  • 批准号:
    7606036
  • 财政年份:
    2006
  • 资助金额:
    $ 19.5万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7375053
  • 财政年份:
    2005
  • 资助金额:
    $ 19.5万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7201220
  • 财政年份:
    2004
  • 资助金额:
    $ 19.5万
  • 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    6980810
  • 财政年份:
    2003
  • 资助金额:
    $ 19.5万
  • 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
  • 批准号:
    6419444
  • 财政年份:
    2000
  • 资助金额:
    $ 19.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了